Alison L. Hannah
- Oncology top 1%
- Molecular Biology top 5%
- Pulmonary and Respiratory Medicine top 2%
- Hematology top 1%
- Cancer Research top 2%
- Co-authors
- Hope S. RugoSara A. HurvitzJohannes EttlLida A. MinaLouis FehrenbacherAlison StopeckAnthony GonçalvèsHenri Roché
- Topics
- Cancer Treatment and Pharmacology (35 papers)Multiple Myeloma Research and Treatments (21 papers)Cancer therapeutics and mechanisms (17 papers)
- Cited by
- OncologyHematologyCancer Research
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Alison L. Hannah
117 papers receiving 4.8k citations
Hit Papers
Peers
Comparison fields: 5 of 113
- Oncology 2.5k
- Molecular Biology 2.5k
- Pulmonary and Respiratory Medicine 1.2k
- Hematology 766
- Cancer Research 763
Countries citing papers authored by Alison L. Hannah
This map shows the geographic impact of Alison L. Hannah's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alison L. Hannah with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alison L. Hannah more than expected).
Fields of papers citing papers by Alison L. Hannah
This network shows the impact of papers produced by Alison L. Hannah. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alison L. Hannah. The network helps show where Alison L. Hannah may publish in the future.
Co-authorship network of co-authors of Alison L. Hannah
This figure shows the co-authorship network connecting the top 25 collaborators of Alison L. Hannah. A scholar is included among the top collaborators of Alison L. Hannah based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alison L. Hannah. Alison L. Hannah is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 45 | |
| 2 | 88 | |
| 3 | 17 | |
| 4 | Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutationbreakdown → | 1401 |
| 5 | 36 | |
| 6 | 7 | |
| 7 | 62 | |
| 8 | 49 | |
| 9 | 49 | |
| 10 | 328 | |
| 11 | 9 | |
| 12 | 15 | |
| 13 | 23 | |
| 14 | 20 | |
| 15 | 10 | |
| 16 | 37 | |
| 17 | 60 | |
| 18 | 4 | |
| 19 | 25 | |
| 20 | Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. | 220 |
About Alison L. Hannah
Alison L. Hannah is a scholar working on Hematology, Oncology and Genetics, having authored 122 papers that have together received 4.9k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (35 papers), Multiple Myeloma Research and Treatments (21 papers) and Cancer therapeutics and mechanisms (17 papers). The work is most often cited by research in Oncology (2.5k citations), Hematology (766 citations) and Cancer Research (763 citations). Alison L. Hannah has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Hope S. Rugo, Sara A. Hurvitz, Johannes Ettl, Lida A. Mina, Louis Fehrenbacher, Alison Stopeck, Anthony Gonçalvès, Henri Roché, Jennifer K. Litton and W. Eiermann. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.